Pfizer touts new Abrysvo results for RSV

Pfizer (NYSE: PFE) today announced positive top-line safety and immunogenicity results from sub-study B of the ongoing pivotal Phase III clinical trial of its respiratory syncytial virus (RSV) vaccine.

The trial evaluated two doses of Abrysvo vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), the US pharma giant noted.

Adults with immunocompromising conditions have an increased risk of developing RSV-LRTD. Sub-study B of the MONeT trial was conducted to assess the safety and immunogenicity of two doses of Abrysvo, administered one month apart, in four groups of immunocompromised adults: those with non-small cell lung cancer, those on hemodialysis due to end-stage renal disease, those with autoimmune inflammatory disorder receiving active immunomodulator therapy, and solid organ transplant recipients. Of the 203 adults enrolled in the sub-study, around half were between the ages of 18 to 59, and about half were 60 years or older.